Oral Oncology
Volume 46, Issue 9 , Pages 644-647 , September 2010

Endothelins and their receptors as biological markers for oral cancer

  • Renata R. Hoffmann

      Affiliations

    • Postgraduate Program of Dental College, PUCRS, Brazil
    • ,
  • Liliane S. Yurgel

      Affiliations

    • Postgraduate Program of Dental College, PUCRS, Brazil
    • Stomatology Service, Hospital São Lucas, PUCRS, Brazil
    • ,
  • Maria M. Campos

      Affiliations

    • Postgraduate Program of Dental College, PUCRS, Brazil
    • Institute of Toxicology, PUCRS, Brazil
    • Corresponding Author InformationCorresponding author at: School of Dentistry, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga, 6681, Partenon, 90619-900 Porto Alegre, Brazil. Tel.: +55 51 3320 3562; fax: +55 51 3320 3626.

Received 9 June 2010 ,Revised 24 June 2010 ,Accepted 25 June 2010.

References 

  1. Girod SC, Pfeiffer P, Ries J, Pape H-D. Proliferative activity and loss of function of tumour supressor genes as “biomarkers” in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 1998;36:252–260
  2. Regezi JA, Jordan RC. Oral cancer in the molecular age. J Calif Dent Assoc. 2001;29(8):578–584
  3. Viet CT, Jordan RC, Schmidt BL. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. J Calif Dent Assoc. 2007;35(12):844–849
  4. Peacock ZS, Pogrel MA, Schimidt BL. Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc. 2008;139(10):1346–1352
  5. Viet CT, Schmidt BL. Understanding oral cancer in the genome era. Head Neck. 2010;DOI 10.1002/hed
  6. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Phisiol. 1985;248:C550–C556
  7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  8. Levin ER. Endothelins. N Eng J Med. 1995;333:356–363
  9. Davenport AP. International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219–226
  10. Kusserow H, Unger T. Vasoacitive peptides, their receptors and drug development. Basic Clin Pharmacol Toxicol. 2004;94:5–12
  11. Goraca A. New views on the role of endothelin. Endocr Regul. 2002;36:161–167
  12. Motte S, Mcentee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110:386–414
  13. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest. 2009;39(S2):74–77
  14. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97(S3):779–784
  15. Ducancel F. Endothelin-like peptides. Cell Mol Life Sci. 2005;62:2828–2839
  16. Yanagisawa M, Masaki T. Endothelin, a novel endothelium-derived peptide. Biochem Pharmacol. 1989;38(12):1877–1883
  17. Gössl M, Lerman A. Endothelin: Beyond a vasoconstrictor. Circulation. 2006;113:1156–1158
  18. Langhmani K, Preisig PA, Alpern RJ. The role of endothelin in proximal tubule próton secretion and the adaptation to a chronic metabolic acidosis. J Nephrol. 2002;15(S5):S75–S87
  19. Plant TD, Zöllner C, Mousa SA, Oksche A. Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the Endothelin-A recptor. Exp Biol Med. 2006;231:1161–1164
  20. Chichorro JG, Zampronio AR, Rae GA. Endothelin ETB recptor sntagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med. 2006;231:1136–1140
  21. Ansai T, Yamamoto E, Awano S, Weixian Yu, Turner AJ, Takehara T. Effects of periodontopathic bacteria on the expression of endothelin-1 in gingival epithelial cells in adults periodontitis. Clin Sci. 2002;103(S48):327s–331s
  22. Yamamoto E, Awano S, Koseki T, Ansai T, Takehara T. Expression of endothelin-1 in gingival epithelial cells. J Periodont Res. 2003;38:417–421
  23. Bagnato A, Spinella F, Rosanò L. Emerging role of the axis in ovarian tumor progression. Endocr Relat Cancer. 2005;12:761–772
  24. Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly target therapy. Can J Physiol Pharmacol. 2008;86:473–484
  25. Bagnato A, Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40:1443–1451
  26. Grimshaw MJ. Endothelins in breast tumor cell invasion. Cancer Letter. 2005;222:129–138
  27. Alanen K, Deng DX, Chakrabarti S. Augmented expression of endothelin-1, endothelin-2, endothelin-3 and endothelin-B receptor in breast carcinoma. Histopathology. 1999;36:161–167
  28. Ishibashi M, Fujita M, Nagai K, Kako M, Furue H, Haku E, et al. Production and secretion of endotelin by hepatocelular carcinoma. J Clin Endocrinol Metab. 1993;76(2):378–383
  29. Lam H-C, Lo G-H, Lee J-K, Lu C-C, Chu C-H, Sun C-C, et al. Salivary immunoreactive endothelin in patients with upper gastrointestinal diseases. J Cardiovasc Pharmacol. 2004;44(S1):S413–S417
  30. Jiao W, Xu J, Pan H, Wang T-Y, Shen Y. Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B. World J Gastroenterol. 2007;13(29):4002–4005
  31. Jiao W, Xu J, Zheng J, Shen Y, Lin L, Li J. Elevation of circulating big ET-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma. BMC Cancer. 2008;15(8):334
  32. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M, Viale G. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging. 2006;50:272–287
  33. Zhang W-M, Zhou J, Ye Q-J. Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sciences. 2008;82:764–771
  34. Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 2005;65(16):7320–7327
  35. Cella D, Petrylak DP, Fishman M, Teigland C, Young J, Mulani P. Role of quality of life in men with metastatic hormone-refractory prostate cancer: How does Atrasentan influence quality of life?. Eur Urol. 2006;49:781–789
  36. Lahav R. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol. 2005;49:173–180
  37. Lan C-Ce, Wu C-S, Cheng C-M, Yu C-L, Chen G-S, Yu H-S. Pigmentation in basal cell carcinoma involves enhanced endothelin-1 expression. Exper Dermatol. 2005;14:528–534
  38. Berger Y, Bernasconi CC, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med. 2006;231:1111–1119
  39. Spinella F, Rosanò L, Elia G, Di Castro V, Natali PG, Bagnato A, et al. Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol. 2004;44(S1):S140–S143
  40. Rosanò L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG, et al. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther. 2006;5(4):833–842
  41. Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, MRet Nicotra, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther. 2006;5(6):1483–1492
  42. Spinella F, Rosanò L, Decandia S, Di Castro V, Albini A, Elia G, et al. Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med. 2006;231:1123–1127
  43. Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, et al. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med. 2006;231:1128–1131
  44. Awano S, Dawson LA, Hunter AR, Turner AJ, Usmani BA. Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation. Int J Cancer. 2006;118:1645–1652
  45. Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients–a pilot study. Oral Oncol. 2007;43(1):37–41
  46. Hans G, Schmidt BL, Strichartz G. Nociceptive sensitization by endothelin-1. Brain Res Rev. 2009;60:36–42
  47. Khodorova A, Montmayer J-P, Strichartz G. Endothelin receptors and pain. J Pain. 2009;10(1):4–28
  48. Pickering V, Gupta RJ, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008;12(3):293–300
  49. Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al. Peripheral endothelin-A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007;11:406–414
  50. Quang PN, Schmidt BL. Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice. The J Pain 2010, in press.
  51. Quang PN, Schmidt BL. Peripheral endothelin-B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain. 2010;149(2):254–262
  52. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3(2):110–116
  53. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. TRENDS Endocrinol Metabol. 2002;14(1):44–50
  54. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer. 2007;14:233–244

PII: S1368-8375(10)00199-5

doi: 10.1016/j.oraloncology.2010.06.015

Oral Oncology
Volume 46, Issue 9 , Pages 644-647 , September 2010

Article Tools

* Image Usage & Resolution